International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

A. Younes, P. Hilden, B. Coiffier, A. Hagenbeek, G. Salles, W. Wilson, J. F. Seymour, K. Kelly, J. Gribben, M. Pfreunschuh, F. Morschhauser, H. Schoder, A. D. Zelenetz, J. Rademaker, R. Advani, N. Valente, C. Fortpied, Thomas Elmer Witzig, L. H. Sehn, A. EngertR. I. Fisher, P. L. Zinzani, M. Federico, M. Hutchings, C. Bollard, M. Trneny, Y. A. Elsayed, K. Tobinai, J. S. Abramson, N. Fowler, A. Goy, M. Smith, Stephen Maxted Ansell, J. Kuruvilla, M. Dreyling, C. Thieblemont, R. F. Little, I. Aurer, M. H.J. Van Oers, K. Takeshita, A. Gopal, S. Rule, S. de Vos, I. Kloos, M. S. Kaminski, M. Meignan, L. H. Schwartz, J. P. Leonard, S. J. Schuster, V. E. Seshan

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new "basket" clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.

Original languageEnglish (US)
Pages (from-to)1436-1447
Number of pages12
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume28
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Lymphoma
Clinical Trials
Neoplasms
Fluorodeoxyglucose F18
Tumor Burden
Positron-Emission Tomography
Multicenter Studies
Therapeutics
Tomography
Genome
Pediatrics

Keywords

  • FDG-PET
  • immunotherapy
  • lymphoma
  • response criteria
  • targeted therapy
  • waterfall plots

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). / Younes, A.; Hilden, P.; Coiffier, B.; Hagenbeek, A.; Salles, G.; Wilson, W.; Seymour, J. F.; Kelly, K.; Gribben, J.; Pfreunschuh, M.; Morschhauser, F.; Schoder, H.; Zelenetz, A. D.; Rademaker, J.; Advani, R.; Valente, N.; Fortpied, C.; Witzig, Thomas Elmer; Sehn, L. H.; Engert, A.; Fisher, R. I.; Zinzani, P. L.; Federico, M.; Hutchings, M.; Bollard, C.; Trneny, M.; Elsayed, Y. A.; Tobinai, K.; Abramson, J. S.; Fowler, N.; Goy, A.; Smith, M.; Ansell, Stephen Maxted; Kuruvilla, J.; Dreyling, M.; Thieblemont, C.; Little, R. F.; Aurer, I.; Van Oers, M. H.J.; Takeshita, K.; Gopal, A.; Rule, S.; de Vos, S.; Kloos, I.; Kaminski, M. S.; Meignan, M.; Schwartz, L. H.; Leonard, J. P.; Schuster, S. J.; Seshan, V. E.

In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 28, No. 7, 01.07.2017, p. 1436-1447.

Research output: Contribution to journalArticle

Younes, A, Hilden, P, Coiffier, B, Hagenbeek, A, Salles, G, Wilson, W, Seymour, JF, Kelly, K, Gribben, J, Pfreunschuh, M, Morschhauser, F, Schoder, H, Zelenetz, AD, Rademaker, J, Advani, R, Valente, N, Fortpied, C, Witzig, TE, Sehn, LH, Engert, A, Fisher, RI, Zinzani, PL, Federico, M, Hutchings, M, Bollard, C, Trneny, M, Elsayed, YA, Tobinai, K, Abramson, JS, Fowler, N, Goy, A, Smith, M, Ansell, SM, Kuruvilla, J, Dreyling, M, Thieblemont, C, Little, RF, Aurer, I, Van Oers, MHJ, Takeshita, K, Gopal, A, Rule, S, de Vos, S, Kloos, I, Kaminski, MS, Meignan, M, Schwartz, LH, Leonard, JP, Schuster, SJ & Seshan, VE 2017, 'International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 28, no. 7, pp. 1436-1447. https://doi.org/10.1093/annonc/mdx097
Younes, A. ; Hilden, P. ; Coiffier, B. ; Hagenbeek, A. ; Salles, G. ; Wilson, W. ; Seymour, J. F. ; Kelly, K. ; Gribben, J. ; Pfreunschuh, M. ; Morschhauser, F. ; Schoder, H. ; Zelenetz, A. D. ; Rademaker, J. ; Advani, R. ; Valente, N. ; Fortpied, C. ; Witzig, Thomas Elmer ; Sehn, L. H. ; Engert, A. ; Fisher, R. I. ; Zinzani, P. L. ; Federico, M. ; Hutchings, M. ; Bollard, C. ; Trneny, M. ; Elsayed, Y. A. ; Tobinai, K. ; Abramson, J. S. ; Fowler, N. ; Goy, A. ; Smith, M. ; Ansell, Stephen Maxted ; Kuruvilla, J. ; Dreyling, M. ; Thieblemont, C. ; Little, R. F. ; Aurer, I. ; Van Oers, M. H.J. ; Takeshita, K. ; Gopal, A. ; Rule, S. ; de Vos, S. ; Kloos, I. ; Kaminski, M. S. ; Meignan, M. ; Schwartz, L. H. ; Leonard, J. P. ; Schuster, S. J. ; Seshan, V. E. / International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). In: Annals of oncology : official journal of the European Society for Medical Oncology. 2017 ; Vol. 28, No. 7. pp. 1436-1447.
@article{ce97a143201d4a0d974e29d8642c9b1d,
title = "International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)",
abstract = "In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new {"}basket{"} clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.",
keywords = "FDG-PET, immunotherapy, lymphoma, response criteria, targeted therapy, waterfall plots",
author = "A. Younes and P. Hilden and B. Coiffier and A. Hagenbeek and G. Salles and W. Wilson and Seymour, {J. F.} and K. Kelly and J. Gribben and M. Pfreunschuh and F. Morschhauser and H. Schoder and Zelenetz, {A. D.} and J. Rademaker and R. Advani and N. Valente and C. Fortpied and Witzig, {Thomas Elmer} and Sehn, {L. H.} and A. Engert and Fisher, {R. I.} and Zinzani, {P. L.} and M. Federico and M. Hutchings and C. Bollard and M. Trneny and Elsayed, {Y. A.} and K. Tobinai and Abramson, {J. S.} and N. Fowler and A. Goy and M. Smith and Ansell, {Stephen Maxted} and J. Kuruvilla and M. Dreyling and C. Thieblemont and Little, {R. F.} and I. Aurer and {Van Oers}, {M. H.J.} and K. Takeshita and A. Gopal and S. Rule and {de Vos}, S. and I. Kloos and Kaminski, {M. S.} and M. Meignan and Schwartz, {L. H.} and Leonard, {J. P.} and Schuster, {S. J.} and Seshan, {V. E.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1093/annonc/mdx097",
language = "English (US)",
volume = "28",
pages = "1436--1447",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

AU - Younes, A.

AU - Hilden, P.

AU - Coiffier, B.

AU - Hagenbeek, A.

AU - Salles, G.

AU - Wilson, W.

AU - Seymour, J. F.

AU - Kelly, K.

AU - Gribben, J.

AU - Pfreunschuh, M.

AU - Morschhauser, F.

AU - Schoder, H.

AU - Zelenetz, A. D.

AU - Rademaker, J.

AU - Advani, R.

AU - Valente, N.

AU - Fortpied, C.

AU - Witzig, Thomas Elmer

AU - Sehn, L. H.

AU - Engert, A.

AU - Fisher, R. I.

AU - Zinzani, P. L.

AU - Federico, M.

AU - Hutchings, M.

AU - Bollard, C.

AU - Trneny, M.

AU - Elsayed, Y. A.

AU - Tobinai, K.

AU - Abramson, J. S.

AU - Fowler, N.

AU - Goy, A.

AU - Smith, M.

AU - Ansell, Stephen Maxted

AU - Kuruvilla, J.

AU - Dreyling, M.

AU - Thieblemont, C.

AU - Little, R. F.

AU - Aurer, I.

AU - Van Oers, M. H.J.

AU - Takeshita, K.

AU - Gopal, A.

AU - Rule, S.

AU - de Vos, S.

AU - Kloos, I.

AU - Kaminski, M. S.

AU - Meignan, M.

AU - Schwartz, L. H.

AU - Leonard, J. P.

AU - Schuster, S. J.

AU - Seshan, V. E.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new "basket" clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.

AB - In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new "basket" clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.

KW - FDG-PET

KW - immunotherapy

KW - lymphoma

KW - response criteria

KW - targeted therapy

KW - waterfall plots

UR - http://www.scopus.com/inward/record.url?scp=85028014921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028014921&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdx097

DO - 10.1093/annonc/mdx097

M3 - Article

C2 - 28379322

AN - SCOPUS:85028014921

VL - 28

SP - 1436

EP - 1447

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 7

ER -